147 related articles for article (PubMed ID: 36526469)
1. Subnanomolar Affinity and Selective Antagonism at α7 Nicotinic Receptor by Combined Modifications of 2-Triethylammonium Ethyl Ether of 4-Stilbenol (MG624).
Bavo F; Pallavicini M; Pucci S; Appiani R; Giraudo A; Oh H; Kneisley DL; Eaton B; Lucero L; Gotti C; Clementi F; Whiteaker P; Bolchi C
J Med Chem; 2023 Jan; 66(1):306-332. PubMed ID: 36526469
[TBL] [Abstract][Full Text] [Related]
2. From 2-Triethylammonium Ethyl Ether of 4-Stilbenol (MG624) to Selective Small-Molecule Antagonists of Human α9α10 Nicotinic Receptor by Modifications at the Ammonium Ethyl Residue.
Bavo F; Pallavicini M; Pucci S; Appiani R; Giraudo A; Eaton B; Lucero L; Gotti C; Moretti M; Whiteaker P; Bolchi C
J Med Chem; 2022 Jul; 65(14):10079-10097. PubMed ID: 35834819
[TBL] [Abstract][Full Text] [Related]
3. Potent Antiglioblastoma Agents by Hybridizing the Onium-Alkyloxy-Stilbene Based Structures of an α7-nAChR, α9-nAChR Antagonist and of a Pro-Oxidant Mitocan.
Bavo F; Pucci S; Fasoli F; Lammi C; Moretti M; Mucchietto V; Lattuada D; Viani P; De Palma C; Budriesi R; Corradini I; Dowell C; McIntosh JM; Clementi F; Bolchi C; Gotti C; Pallavicini M
J Med Chem; 2018 Dec; 61(23):10531-10544. PubMed ID: 30403486
[TBL] [Abstract][Full Text] [Related]
4. Selective effects of a 4-oxystilbene derivative on wild and mutant neuronal chick alpha7 nicotinic receptor.
Maggi L; Palma E; Eusebi F; Moretti M; Balestra B; Clementi F; Gotti C
Br J Pharmacol; 1999 Jan; 126(1):285-95. PubMed ID: 10051147
[TBL] [Abstract][Full Text] [Related]
5. Evidence of a dual mechanism of action underlying the anti-proliferative and cytotoxic effects of ammonium-alkyloxy-stilbene-based α7- and α9-nicotinic ligands on glioblastoma cells.
Pucci S; Bolchi C; Bavo F; Pallavicini M; De Palma C; Renzi M; Fucile S; Benfante R; Di Lascio S; Lattuada D; Bessereau JL; D'Alessandro M; Risson V; Zoli M; Clementi F; Gotti C
Pharmacol Res; 2022 Jan; 175():105959. PubMed ID: 34756924
[TBL] [Abstract][Full Text] [Related]
6. Small molecule ligands for α9 * and α7 nicotinic receptors: A survey and an update, respectively.
Giraudo A; Pallavicini M; Bolchi C
Pharmacol Res; 2023 Jul; 193():106801. PubMed ID: 37236412
[TBL] [Abstract][Full Text] [Related]
7. Side Groups Convert the α7 Nicotinic Receptor Agonist Ether Quinuclidine into a Type I Positive Allosteric Modulator.
Viscarra F; Chrestia JF; Sanchez Y; Pérez EG; Biggin PC; Bouzat C; Bermudez I; López JJ
ACS Chem Neurosci; 2023 Aug; 14(16):2876-2887. PubMed ID: 37535446
[TBL] [Abstract][Full Text] [Related]
8. New Alpha9 nAChR Ligands Based on a 5-(Quinuclidin-3-ylmethyl)-1,2,4-oxadiazole Scaffold.
Dallanoce C; Richter K; Stokes C; Papotto C; Andleeb H; Thakur GA; Kerr A; Grau V; Papke RL
ACS Chem Neurosci; 2024 Feb; 15(4):827-843. PubMed ID: 38335726
[TBL] [Abstract][Full Text] [Related]
9. MG624, an α7-nAChR antagonist, inhibits angiogenesis via the Egr-1/FGF2 pathway.
Brown KC; Lau JK; Dom AM; Witte TR; Luo H; Crabtree CM; Shah YH; Shiflett BS; Marcelo AJ; Proper NA; Hardman WE; Egleton RD; Chen YC; Mangiarua EI; Dasgupta P
Angiogenesis; 2012 Mar; 15(1):99-114. PubMed ID: 22198237
[TBL] [Abstract][Full Text] [Related]
10. α9- and α7-containing receptors mediate the pro-proliferative effects of nicotine in the A549 adenocarcinoma cell line.
Mucchietto V; Fasoli F; Pucci S; Moretti M; Benfante R; Maroli A; Di Lascio S; Bolchi C; Pallavicini M; Dowell C; McIntosh M; Clementi F; Gotti C
Br J Pharmacol; 2018 Jun; 175(11):1957-1972. PubMed ID: 28726253
[TBL] [Abstract][Full Text] [Related]
11. An Evolving Therapeutic Rationale for Targeting the α
Deutsch SI; Burket JA
Curr Top Behav Neurosci; 2020; 45():167-208. PubMed ID: 32468495
[TBL] [Abstract][Full Text] [Related]
12. Calcium imaging with genetically encoded sensor Case12: Facile analysis of α7/α9 nAChR mutants.
Shelukhina I; Spirova E; Kudryavtsev D; Ojomoko L; Werner M; Methfessel C; Hollmann M; Tsetlin V
PLoS One; 2017; 12(8):e0181936. PubMed ID: 28797116
[TBL] [Abstract][Full Text] [Related]
13. Distinctive Roles for α7*- and α9*-Nicotinic Acetylcholine Receptors in Inflammatory and Autoimmune Responses in the Murine Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis.
Liu Q; Whiteaker P; Morley BJ; Shi FD; Lukas RJ
Front Cell Neurosci; 2017; 11():287. PubMed ID: 29018331
[TBL] [Abstract][Full Text] [Related]
14. Discovery, synthesis, and structure activity of a highly selective alpha7 nicotinic acetylcholine receptor antagonist.
Whiteaker P; Christensen S; Yoshikami D; Dowell C; Watkins M; Gulyas J; Rivier J; Olivera BM; McIntosh JM
Biochemistry; 2007 Jun; 46(22):6628-38. PubMed ID: 17497892
[TBL] [Abstract][Full Text] [Related]
15. Advances in the discovery of novel positive allosteric modulators of the alpha7 nicotinic acetylcholine receptor.
Faghih R; Gfesser GA; Gopalakrishnan M
Recent Pat CNS Drug Discov; 2007 Jun; 2(2):99-106. PubMed ID: 18221220
[TBL] [Abstract][Full Text] [Related]
16. Canonical and Novel Non-Canonical Cholinergic Agonists Inhibit ATP-Induced Release of Monocytic Interleukin-1β via Different Combinations of Nicotinic Acetylcholine Receptor Subunits α7, α9 and α10.
Zakrzewicz A; Richter K; Agné A; Wilker S; Siebers K; Fink B; Krasteva-Christ G; Althaus M; Padberg W; Hone AJ; McIntosh JM; Grau V
Front Cell Neurosci; 2017; 11():189. PubMed ID: 28725182
[TBL] [Abstract][Full Text] [Related]
17. Differential involvement of α4β2, α7 and α9α10 nicotinic acetylcholine receptors in B lymphocyte activation in vitro.
Koval L; Lykhmus O; Zhmak M; Khruschov A; Tsetlin V; Magrini E; Viola A; Chernyavsky A; Qian J; Grando S; Komisarenko S; Skok M
Int J Biochem Cell Biol; 2011 Apr; 43(4):516-24. PubMed ID: 21146628
[TBL] [Abstract][Full Text] [Related]
18. New quinoline derivatives as nicotinic receptor modulators.
Manetti D; Bellucci C; Dei S; Teodori E; Varani K; Spirova E; Kudryavtsev D; Shelukhina I; Tsetlin V; Romanelli MN
Eur J Med Chem; 2016 Mar; 110():246-58. PubMed ID: 26840365
[TBL] [Abstract][Full Text] [Related]
19. JN403, in vitro characterization of a novel nicotinic acetylcholine receptor alpha7 selective agonist.
Feuerbach D; Nozulak J; Lingenhoehl K; McAllister K; Hoyer D
Neurosci Lett; 2007 Apr; 416(1):61-5. PubMed ID: 17314009
[TBL] [Abstract][Full Text] [Related]
20. Drugs selective for nicotinic receptor subtypes: a real possibility or a dream?
Gotti C; Carbonnelle E; Moretti M; Zwart R; Clementi F
Behav Brain Res; 2000 Aug; 113(1-2):183-92. PubMed ID: 10942044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
